{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:07:53Z","timestamp":1790032073996,"version":"4.0.1"},"reference-count":59,"publisher":"Georg Thieme Verlag KG","issue":"09","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pneumologie"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>Biologika sind Mittel der 1. Wahl bei Patienten mit schwerem, unzureichend kontrolliertem Asthma und k\u00f6nnen zu einer starken Senkung (oder sogar vollst\u00e4ndigen Vermeidung) von Exazerbationen und des Bedarfs an nebenwirkungsreichen systemischen Kortikosteroiden und zu einer deutlichen Besserung der Asthma-Kontrolle und der Lungenfunktion bei schwerem Asthma f\u00fchren. Aufgrund der hohen Jahrestherapiekosten einer Biologikatherapie besteht ein berechtigtes Interesse seitens der Kostentr\u00e4ger an einem leitlinien- und zulassungskonformen und wirtschaftlichen Einsatz von Biologika bei schwerem Asthma, andererseits besteht ein berechtigtes Interesse seitens der behandelnden \u00c4rztinnen und \u00c4rzte an einer regresssicheren Verordnung dieser Biologika.<\/jats:p>\n                  <jats:p>In einer Analyse der Literatur und der Zulassungen wurde in Zusammenschau mit den Erfahrungen der beteiligten Autoren die Evidenz zur Therapie mit den f\u00fcr schweres Asthma zugelassenen Biologika Omalizumab, Mepolizumab, Reslizumab, Benralizumab, Dupilumab, Tezepelumab und Depemokimab zusammengetragen.<\/jats:p>\n                  <jats:p>Basierend auf den Leitlinienempfehlung und Zulassungen werden Empfehlungen f\u00fcr die Anwendung der genannten Biologika im deutschen Gesundheitssystem gegeben. In einer gemeinsamen Anstrengung verschiedener Fachgesellschaften (AeDA, DGP, BdP, GAN, DGAKI, GPP, GPA) wurden Dokumentationsb\u00f6gen f\u00fcr alle f\u00fcr schweres Asthma zugelassenen Biologika erstellt, die als Grundlage der Dokumentation dienen k\u00f6nnen. Es wurden hierbei sowohl B\u00f6gen f\u00fcr die Einleitung einer Biologikatherapie als auch B\u00f6gen zur Verlaufsdokumentation einer Biologikatherapie bei schwerem Asthma entwickelt.<\/jats:p>\n                  <jats:p>Die neuen Dokumentationsb\u00f6gen fassen praxistauglich alle wichtigen Eckpunkte der Biologikaverordnung und der Beurteilung des Biologikaansprechens bei schwerem Asthma auf einer Seite zusammen und dienen sowohl der Sicherstellung einer leitliniengerechten und zulassungskonformen Verordnung als auch der Vermeidung von Arzneimittelregressen.<\/jats:p>","DOI":"10.1055\/a-2842-7870","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T22:45:52Z","timestamp":1779144352000},"page":"631-640","source":"Crossref","is-referenced-by-count":0,"title":["Positionspapier zur Dokumentation von Biologikatherapien bei schwerem Asthma: Empfehlungen von AeDA, DGP, BdP, GAN, DGAKI, GPP und GPA"],"prefix":"10.1055","volume":"80","author":[{"given":"Marek","family":"Lommatzsch","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsmedizin Rostock, Deutschland","place":["Rostock"],"department":["Klinik f\u00fcr Pneumologie, Allergologie und Internistische Intensivmedizin, Department f\u00fcr Innere Medizin"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Buhl","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz, Rheinland-Pfalz, Deutschland","place":["Mainz"],"department":["Klinik f\u00fcr Pneumologie, Zentrum f\u00fcr Thoraxerkrankungen"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randolf","family":"Brehler","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum M\u00fcnster, NRW, Deutschland","place":["M\u00fcnster"],"department":["Klinik f\u00fcr Hautkrankheiten"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eckard","family":"Hamelmann","sequence":"additional","affiliation":[{"name":"Medizinische Fakult\u00e4t der Universit\u00e4t Bielefeld, NRW, Deutschland","place":["Bielefeld"],"department":["Kinderzentrum Bethel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Joest","sequence":"additional","affiliation":[{"name":"Lungen- und Allergiezentrum, NRW, Deutschland","place":["Bonn"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"aufm Kampe","sequence":"additional","affiliation":[{"name":"Lungen- und Allergiezentrum, NRW, Deutschland","place":["Bonn"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Korn","sequence":"additional","affiliation":[{"name":"IKF, Deutschland","place":["Mainz"],"department":["Pneumologie"]},{"name":"Universit\u00e4tsKlinikum Heidelberg, Baden-W\u00fcrttemberg, Deutschland","place":["Heidelberg"],"department":["Thoraxklinik"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Lampert","sequence":"additional","affiliation":[{"name":"Praxis Lunge im Zentrum, Bayern, Deutschland","place":["Erlangen"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"M\u00fclleneisen","sequence":"additional","affiliation":[{"name":"Asthma und Allergiezentrum, Nordrhein-Westfalen, Deutschland","place":["Leverkusen"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Taube","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsmedizin Essen, Deutschland","place":["Essen"],"department":["Ruhrlandklinik \u2013 Klinik f\u00fcr Pneumologie"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordis","family":"Trischler","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Frankfurt, HE, Deutschland","place":["Frankfurt"],"department":["Klinik f\u00fcr Kinder- und Jugendmedizin"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Vogelberg","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Carl Gustav Carus an der Technischen Universit\u00e4t Dresden, SN, Deutschland","place":["Dresden"],"department":["Klinik und Poliklinik f\u00fcr Kinder- und Jugendmedizin"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Schmitz","sequence":"additional","affiliation":[{"name":"MVZ Pf\u00e4lzer Land GmbH, Deutschland","place":["Kaiserslautern"],"department":["Zentrum f\u00fcr Atemwegserkrankungen"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludger","family":"Klimek","sequence":"additional","affiliation":[{"name":"Zentrum f\u00fcr Rhinologie und Allergologie, Deutschland","place":["Wiesbaden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/S0140-6736(22)00331-2","article-title":"Disease-modifying anti-asthmatic drugs","volume":"399","author":"M Lommatzsch","year":"2022","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/S2213-2600(24)00383-7","article-title":"Asthma: epidemiology, risk factors, and opportunities for prevention and\n          treatment","volume":"13","author":"SM Jayasooriya","year":"2025","journal-title":"Lancet Respir Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1007\/s00103-012-1652-7","article-title":"H\u00e4ufigkeit allergischer Erkrankungen in Deutschland","volume":"56","author":"U Langen","year":"2013","journal-title":"Bundesgesundheitsblatt \u2013 Gesundheitsforschung \u2013 Gesundheitsschutz"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"103050","DOI":"10.1016\/j.eclinm.2024.103050","article-title":"Roads to remission: evolving treatment concepts in type 2 inflammatory diseases","volume":"80","author":"M Lommatzsch","year":"2025","journal-title":"EClinicalMedicine"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S2213-2600(24)00304-7","article-title":"Asthma remission: a call for a globally standardised definition","volume":"13","author":"M Lommatzsch","year":"2025","journal-title":"Lancet Respir Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S2213-2600(24)00293-5","article-title":"Clinical remission attainment, definitions, and correlates among patients with\n          severe asthma treated with biologics: a systematic review and meta-analysis","volume":"13","author":"A Shackleford","year":"2025","journal-title":"Lancet Respir Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S2213-2600(25)00174-2","article-title":"Eosinophils in asthma phenotypes: perpetrators or guilty by\n          association?","volume":"13","author":"M Lommatzsch","year":"2025","journal-title":"Lancet Respir Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1055\/a-2070-2135","article-title":"Diagnosis and treatment of asthma: a guideline for respiratory specialists 2023 \u2013 published by the German Respiratory Society (DGP) e.\u200aV.","volume":"77","author":"M Lommatzsch","year":"2023","journal-title":"Pneumologie"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S2213-2600(22)00490-8","article-title":"A(2)BCD: a concise guide for asthma management","volume":"11","author":"M Lommatzsch","year":"2023","journal-title":"Lancet Respir Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s15006-023-2646-0","article-title":"Die 4 wichtigsten Bausteine der Asthmadiagnostik in der Praxis","volume":"165","author":"M Lommatzsch","year":"2023","journal-title":"MMW \u2013 Fortschritte der Medizin"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3238\/arztebl.2014.0847","article-title":"Severe asthma: definition, diagnosis and treatment","volume":"111","author":"M Lommatzsch","year":"2014","journal-title":"Dtsch Arztebl Int"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"KF Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1055\/a-2070-2135","article-title":"Diagnosis and treatment of asthma: a guideline for respiratory specialists 2023 \u2013 published by the German Respiratory Society (DGP) e.\u200aV.","volume":"77","author":"M Lommatzsch","year":"2023","journal-title":"Pneumologie"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.jaip.2022.03.019","article-title":"Characterization of Asthma by Age of Onset: A Multi-Database Cohort\n          Study","volume":"10","author":"EJ Baan","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1016\/j.jaip.2023.05.047","article-title":"Response to Biologics and Clinical Remission in the Adult German Asthma Net Severe\n          Asthma Registry Cohort","volume":"11","author":"K Milger","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1111\/all.14997","article-title":"Type 2 biomarker expression (FeNO and blood eosinophils) is higher in severe adult-onset than in severe early-onset asthma","volume":"76","author":"M Lommatzsch","year":"2021","journal-title":"Allergy"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaip.2025.01.005","article-title":"Impact of Smoking on Biological Treatment Response in Patients From the German\n          Severe Asthma (GAN) Registry","volume":"13","author":"S Stoshikj","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jaip.2023.10.012","article-title":"Tobacco Exposure and Efficacy of Biologic Therapy in Patients With Severe Asthma:\n          A Nationwide Study From the Danish Severe Asthma Register","volume":"12","author":"M Baastrup Soendergaard","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1159\/000534922","article-title":"Response to Various Biologics in Patients with Both Asthma and Chronic Obstructive Pulmonary Disease","volume":"102","author":"M Lommatzsch","year":"2023","journal-title":"Respiration"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","article-title":"Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype","volume":"391","author":"DJ Jackson","year":"2024","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(25)00197-7","article-title":"Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials","volume":"405","author":"P Gevaert","year":"2025","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1136\/thoraxjnl-2013-203738","article-title":"Against all odds: anti-IgE for intrinsic asthma?","volume":"69","author":"M Lommatzsch","year":"2014","journal-title":"Thorax"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1055\/s-0043-102070","article-title":"IgE and Anti-IgE in Asthma: A Chequered History","volume":"71","author":"M Lommatzsch","year":"2017","journal-title":"Pneumologie"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1016\/j.jaip.2022.04.015","article-title":"Perceptions on Home-Administration of Biologics in the Context of Severe Asthma: An International Qualitative Study","volume":"10","author":"B Flokstra-de Blok","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref26","first-page":"419","article-title":"Home-based treatment of biologics for asthma: who, what, where, when and why","volume":"16","author":"F Menzella","year":"2022","journal-title":"Expert Rev Respir Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1016\/j.jaip.2021.01.011","article-title":"Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis\n          of Observational Studies","volume":"9","author":"J Bousquet","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"Cd010834","DOI":"10.1002\/14651858.CD010834.pub4","article-title":"Anti-IL-5 therapies for asthma","volume":"7","author":"HA Farne","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis","volume":"376","author":"ME Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis","volume":"390","author":"ME Wechsler","year":"2024","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A\u00a0phase III, randomized, placebo-controlled trial","volume":"146","author":"F Roufosse","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised,\n          double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"JK Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1056\/NEJMoa2413181","article-title":"Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype","volume":"392","author":"FC Sciurba","year":"2025","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma","volume":"378","author":"M Castro","year":"2018","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa2106567","article-title":"Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma","volume":"385","author":"LB Bacharier","year":"2021","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"A Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"C Bachert","year":"2019","journal-title":"Lancet"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1056\/NEJMoa2205982","article-title":"Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis","volume":"387","author":"ES Dellon","year":"2022","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S2213-2600(24)00409-0","article-title":"Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a\n          pooled analysis of two phase 3, randomised, double-blind, placebo-controlled\n          trials","volume":"13","author":"SP Bhatt","year":"2025","journal-title":"Lancet Respir Med"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S2213-2600(21)00023-0","article-title":"Neutrophilic asthma: misconception or misnomer?","volume":"9","author":"P Nair","year":"2021","journal-title":"Lancet Respir Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1056\/NEJMoa2414482","article-title":"Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps","volume":"392","author":"BJ Lipworth","year":"2025","journal-title":"N Engl J Med"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.anai.2023.08.021","article-title":"Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry","volume":"132","author":"G Scelo","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1111\/all.14964","article-title":"Eosinophilic pleural effusion and stroke with cutaneous vasculitis: Two cases of dupilumab-induced hypereosinophilia","volume":"76","author":"M Lommatzsch","year":"2021","journal-title":"Allergy"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s10875-025-01914-x","article-title":"Dupilumab-induced Eosinophilic Granulomatosis with Polyangiitis Complicated by Peripheral Neuropathic Pain: a Case Report and Literature Review","volume":"45","author":"J Wu","year":"2025","journal-title":"J Clin Immunol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1055\/a-2014-4350","article-title":"Criteria for evaluation of response to biologics in severe asthma \u2013 the Biologics Asthma Response Score (BARS)","volume":"77","author":"K Milger","year":"2023","journal-title":"Pneumologie"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1111\/all.15379","article-title":"Safety of combining biologics in severe asthma: Asthma-related and unrelated combinations","volume":"77","author":"M Lommatzsch","year":"2022","journal-title":"Allergy"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.2147\/JAA.S340684","article-title":"Feasibility of Discontinuing Biologics in Severe Asthma: An Algorithmic\n          Approach","volume":"14","author":"K Hamada","year":"2021","journal-title":"J Asthma Allergy"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"e01158","DOI":"10.1002\/rcr2.1158","article-title":"Severe asthma remaining well-controlled after mepolizumab discontinuation: A case\n          report and literature review","volume":"11","author":"T Matsuyama","year":"2023","journal-title":"Respirol Case Rep"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00396-2021","article-title":"Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)","volume":"59","author":"WC Moore","year":"2022","journal-title":"Eur Respir J"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/thoraxjnl-2017-210017","article-title":"Duration of the efficacy of omalizumab after treatment discontinuation in \u2018real life\u2019 severe asthma","volume":"73","author":"MDC Vennera","year":"2018","journal-title":"Thorax"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1635540","DOI":"10.3389\/falgy.2025.1635540","article-title":"Case Report: Extending dosing intervals of biologics in adults severe asthma: a case series","volume":"6","author":"T Harada","year":"2025","journal-title":"Front Allergy"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"100703","DOI":"10.1016\/j.waojou.2022.100703","article-title":"Extension of mepolizumab injection intervals as potential of saving costs in well controlled patients with severe eosinophilic asthma","volume":"15","author":"G B\u00f6lke","year":"2022","journal-title":"World Allergy Organ J"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0140-6736(23)02284-5","article-title":"Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL): a randomised, multicentre, open-label, phase 4 study","volume":"403","author":"DJ Jackson","year":"2024","journal-title":"Lancet"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1055\/a-1197-0136","article-title":"Positionspapier: Anwendung von Biologika bei chronischer Rhinosinusitis mit\n          Polyposis nasi (CRSwNP) im deutschen Gesundheitssystem \u2013 Empfehlungen des \u00c4rzteverbandes\n          Deutscher Allergologen (AeDA) und der AGs Klinische Immunologie, Allergologie und\n          Umweltmedizin und Rhinologie und Rhinochirurgie der Deutschen Gesellschaft f\u00fcr\n          HNO-Heilkunde, Kopf- und Halschirurgie (DGHNOKHC)","volume":"99","author":"L Klimek","year":"2020","journal-title":"Laryngorhinootologie"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1055\/a-1644-4066","article-title":"Positionspapier: Empfehlungen zur Anwendung von Omalizumab bei\u00a0chronischer\n          Rhinosinusitis mit Polyposis nasi (CRSwNP) im deutschen Gesundheitssystem \u2013 Empfehlungen\n          des \u00c4rzteverbandes Deutscher Allergologen (AeDA) und der AGs Klinische Immunologie,\n          Allergologie und Umweltmedizin und Rhinologie und Rhinochirurgie der Deutschen\n          Gesellschaft f\u00fcr HNO-Heilkunde, Kopf- und Halschirurgie (DGHNOKHC)","volume":"100","author":"L Klimek","year":"2021","journal-title":"Laryngorhinootologie"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40629-022-00220-x","article-title":"Indicating biologics for chronic rhinosinusitis with nasal polyps (CRSwNP)","volume":"31","author":"L Klimek","year":"2022","journal-title":"Allergo Journal International"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1055\/a-1752-8462","article-title":"Positionspapier: Empfehlungen zur Anwendung von Mepolizumab bei chronischer\n          Rhinosinusitis mit Polyposis nasi (CRSwNP) im deutschen Gesundheitssystem \u2013 Empfehlungen\n          des \u00c4rzteverbandes Deutscher Allergologen (AeDA) und der AGs Klinische Immunologie,\n          Allergologie und Umweltmedizin und Rhinologie und Rhinochirurgie der Deutschen\n          Gesellschaft f\u00fcr HNO-Heilkunde, Kopf- und Hals-Chirurgie (DGHNO-KHC)","volume":"101","author":"L Klimek","year":"2022","journal-title":"Laryngorhinootologie"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1016\/s0140-6736(00)03496-6","article-title":"Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response","volume":"356","author":"MJ Leckie","year":"2000","journal-title":"Lancet"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"2400512","DOI":"10.1183\/13993003.00512-2024","article-title":"Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled trial","volume":"64","author":"GM Gauvreau","year":"2024","journal-title":"Eur Respir J"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/S2213-2600(24)00174-7","article-title":"An international consensus on the use of asthma biologics in pregnancy","volume":"13","author":"J Naftel","year":"2025","journal-title":"Lancet Respir Med"}],"container-title":["Pneumologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2842-7870.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T22:39:34Z","timestamp":1790030374000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2842-7870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":59,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2026,9,21]]},"published-print":{"date-parts":[[2026,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2842-7870","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0934-8387","1438-8790"],"issn-type":[{"value":"0934-8387","type":"print"},{"value":"1438-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]}}}